ArticleThe oncologist2026

Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer.

Andrea House et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.